Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
518 Leser
Artikel bewerten:
(2)

Ossiam FTSE 100 Minimum Variance UCITS ETF 1C (GBP): Liquidation

Finanznachrichten News

DJ Liquidation

Ossiam FTSE 100 Minimum Variance UCITS ETF 1C (GBP) (UKMV) Liquidation 13-Jun-2022 / 13:53 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

----------------------------------------------------------------------------------------------------------------------- OSSIAM LUX

Société d'investissement à capital variable

Registered office: 49 Avenue J.F. Kennedy, L-1855 Luxembourg - Grand Duchy of Luxembourg RCS Number B. 160 071

(the "Company")

Luxembourg, May 16th 2022,

Dear Shareholders,

We would like to inform you that the board of directors of the Company (the "Board") has resolved, in accordance with article 24 of the articles of incorporation of the Company, to liquidate the following sub- fund:

Name of the sub-fund       Shareclass     ISIN 
Ossiam FTSE100 Minimum Variance UCITS ETF 1C (GBP) LU0705291739 

(the "Sub-Fund").

The Sub-Fund has demonstrated small levels of demand and assets under management, while focusing on key areas of growth with the intention of bringing the sub-funds of the Company in line with current and future investor demand for better serving the needs of shareholders.

The liquidation of the Sub-Fund will take place on June, 22nd 2022 (the "Liquidation Date"). 1. Primary markets

Redemption or subscription requests for shares in the Sub-Fund (the "Shares") may be made in the usual manner for processing in accordance with the prospectus of the Company (the "Prospectus") prior to the last trading date on the primary markets (the "Last Trading Date"). Only shareholders who qualify as autorised participants may subscribe and redeem Shares on the primary market.

The Last Trading Date on the primary market will take place on June 15th, 2022. From the day after the Last Trading Date to the Liquidation Date, no further subscriptions and redemptions will be accepted.

Such redemptions will be free of redemption charge up to the Last Trading Date but taking into account actual realization prices of investments and realization expenses.

Following the liquidation of the Sub-Fund, the liquidation proceeds will be distributed to the remaining shareholders proportionnally to the number of Shares held by each shareholder prior to the liquidation. 2. Secondary markets

Due to the liquidation of the Sub-Fund, the Board has resolved to cancel the listing of the share class UCITS ETF 1C (GBP) of the Sub-Fund on the following Stock Exchanges on June 10th, 2022 (the "Last Exchange Trading Date") in accordance with the terms and conditions of the Prospectus.

The Board has also resolved to cancel the right of the Sub-Fund to be traded on the following Stock Exchanges with effect as of the business day following the "Last Exchange Trading Date" (the "Delisting Date"):

Last Exchange 
                                           Trading 
Sub-Fund           Shareclass    ISIN     Stock Exchanges               Delisting Date 
                                           Date 
                               Luxembourg Stock 
                               Exchange 
 
               UCITS ETF 1C                      June 10th, 2022   June 13th, 
Ossiam FTSE 100 Minimum    (GBP)       LU0705291739 London Stock Exchange            2022 
Variance 

Please note that the Company does not charge any redemption charge (the "Redemption Charge") for the sale of Shares in the secondary market. However, shareholders should note that orders in the secondary market may incur costs over which the Company has no control and to which the above disapplication of the Redemption Charge does not apply. 3. Tax

Shareholders of the Sub-Fund should be aware that the liquidation, redemption or exchange of Shares may have tax consequences. Shareholders should consult their own professional advisers as to the specific tax implications of the termination under the laws of the countries of their nationality, residence, domicile or incorporation. If any of the above is not clear you should seek advice from your stockbroker, bank manager, legal adviser, accountant or other independent financial advisor. 4. General information

Liquidation proceeds which may not be distributed to their beneficiaries upon the implementation of the redemption will be deposited with the Caisse de Consignation (the Luxembourg public trust office) on behalf of the persons entitled thereto as soon as possible after the payment date. Should you require further information as to the action you should take, please contact your final advisor.

From the date of this letter up to and including the Liquidation Date (the "Liquidation Period"), OSSIAM will seek to continue to manage the Fund in accordance with its investment objective and policy and in accordance with the UCITS rules as they apply in Luxembourg. However, in seeking to terminate the Fund in shareholders' best interests the Fund may not always be compliant with its investment objective and policy or with the UCITS rules during the Liquidation Period.

Shareholders are also informed that the next Prospectus will take into account the liquidation of the Sub- Fund.

Shareholders are informed that, by derogation of the provisions contained in the Prospectus in the Chapter entitled "Charges and Expenses", the liquidation expenses shall not be borne by the shareholders of the Sub-Fund but will be borne by OSSIAM, acting as management company of the Company.

Any further information in relation to the termination of the Sub-Fund may be obtained by sending an email to info@ossiam.com.

Yours faithfully,

The Board of directors of Ossiam Lux

-----------------------------------------------------------------------------------------------------------------------

ISIN:     LU0705291739 
Category Code: MSCH 
TIDM:     UKMV 
LEI Code:   5493004RIQY8MZI3LH24 
Sequence No.: 167952 
EQS News ID:  1374379 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1374379&application_name=news

(END) Dow Jones Newswires

June 13, 2022 08:53 ET (12:53 GMT)

© 2022 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.